Atom Investors LP Purchases Shares of 62,095 AtriCure, Inc. (NASDAQ:ATRC)

Atom Investors LP purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 62,095 shares of the medical device company's stock, valued at approximately $1,741,000. Atom Investors LP owned about 0.13% of AtriCure as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ATRC. Arcadia Investment Management Corp MI bought a new stake in shares of AtriCure in the 3rd quarter valued at about $28,000. Comerica Bank increased its position in shares of AtriCure by 70.5% during the first quarter. Comerica Bank now owns 2,522 shares of the medical device company's stock worth $77,000 after buying an additional 1,043 shares during the period. Quest Partners LLC lifted its holdings in AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock valued at $134,000 after buying an additional 1,626 shares during the period. nVerses Capital LLC boosted its position in AtriCure by 733.3% during the third quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company's stock valued at $140,000 after acquiring an additional 4,400 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC grew its holdings in AtriCure by 32.1% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company's stock worth $222,000 after acquiring an additional 2,368 shares during the period. Institutional investors own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ATRC. JPMorgan Chase & Co. raised their price objective on shares of AtriCure from $30.00 to $40.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. UBS Group increased their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Needham & Company LLC upped their price target on AtriCure from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their price objective on AtriCure from $49.00 to $53.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, StockNews.com upgraded shares of AtriCure from a "sell" rating to a "hold" rating in a research note on Saturday, September 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.

AtriCure Stock Performance

ATRC stock traded down $0.54 during midday trading on Tuesday, hitting $36.52. The company's stock had a trading volume of 146,425 shares, compared to its average volume of 709,599. The stock's 50-day moving average price is $31.87 and its 200 day moving average price is $26.52. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -43.63 and a beta of 1.40. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $39.04.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The firm had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. During the same period in the prior year, the firm earned ($0.20) EPS. The company's revenue was up 17.9% compared to the same quarter last year. On average, equities analysts forecast that AtriCure, Inc. will post -0.72 EPS for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.